Aleksandra Zgierska1, David Rabago, Megan Zuelsdorff, Christopher Coe, Michael Miller, Michael Fleming. 1. From the Department of Family Medicine (AZ, DR, MZ, MM, MF), University of Wisconsin School of Medicine and Public Health, Madison, WI; Department of Psychology (CC), University of Wisconsin, Madison, WI; NewStart Alcohol & Drug Treatment Program (MM), Meriter Hospital, Madison, WI.
Abstract
OBJECTIVES: : Meditation is a promising treatment for alcohol dependence. This 16-week prospective case series was designed to gather preliminary data about the efficacy of meditation for relapse prevention and to evaluate study methods feasibility. METHODS: : Nineteen adult alcohol-dependent graduates of an intensive outpatient program were enrolled. Fifteen subjects completed the 8-week meditation course supplemented by at-home meditation and "standard of care" therapy. Outcome measures included surveys and 2 stress-responsive biomarkers. RESULTS: : Subjects (N = 19, 38.4 standard deviation [SD] = 8.6-year-old) were abstinent for 30.9 (SD = 22.2) days at enrollment. Completers (N = 15) attended 82% of meditation course sessions and meditated on average 4.6 (SD = 1.1) days per week; they were abstinent on 94.5% (SD = 7.4) of study days, with 47% reporting complete abstinence and 47% reporting 1 or more heavy drinking days. Their severity of depression, anxiety, stress (P < 0.05), and craving (P < 0.08), documented relapse triggers, decreased, and the degree of mindfulness increased (P < 0.05). The meditation course was rated as a "very important" (8.7/10, SD = 1.8) and "useful relapse prevention tool" (8.5/10, SD = 2.1); participants reported being "very likely" to continue meditating (9.0/10, SD = 1.5). "Gaining skills to reduce stress," "coping with craving," and "good group support" were the most common qualitative comments about the course value. Compared with baseline, at 16 weeks, interleukin-6 levels decreased (N = 12, P = 0.05); cortisol levels (N = 10) were reduced but not significantly. There were no adverse events or side effects. CONCLUSIONS: : Meditation may be an effective adjunctive therapy for relapse prevention in alcohol dependence, worthy of investigation in a larger trial. The study methods are appropriate for such a trial.
OBJECTIVES: : Meditation is a promising treatment for alcohol dependence. This 16-week prospective case series was designed to gather preliminary data about the efficacy of meditation for relapse prevention and to evaluate study methods feasibility. METHODS: : Nineteen adult alcohol-dependent graduates of an intensive outpatient program were enrolled. Fifteen subjects completed the 8-week meditation course supplemented by at-home meditation and "standard of care" therapy. Outcome measures included surveys and 2 stress-responsive biomarkers. RESULTS: : Subjects (N = 19, 38.4 standard deviation [SD] = 8.6-year-old) were abstinent for 30.9 (SD = 22.2) days at enrollment. Completers (N = 15) attended 82% of meditation course sessions and meditated on average 4.6 (SD = 1.1) days per week; they were abstinent on 94.5% (SD = 7.4) of study days, with 47% reporting complete abstinence and 47% reporting 1 or more heavy drinking days. Their severity of depression, anxiety, stress (P < 0.05), and craving (P < 0.08), documented relapse triggers, decreased, and the degree of mindfulness increased (P < 0.05). The meditation course was rated as a "very important" (8.7/10, SD = 1.8) and "useful relapse prevention tool" (8.5/10, SD = 2.1); participants reported being "very likely" to continue meditating (9.0/10, SD = 1.5). "Gaining skills to reduce stress," "coping with craving," and "good group support" were the most common qualitative comments about the course value. Compared with baseline, at 16 weeks, interleukin-6 levels decreased (N = 12, P = 0.05); cortisol levels (N = 10) were reduced but not significantly. There were no adverse events or side effects. CONCLUSIONS: : Meditation may be an effective adjunctive therapy for relapse prevention in alcohol dependence, worthy of investigation in a larger trial. The study methods are appropriate for such a trial.
Authors: Sarah Bowen; Katie Witkiewitz; Tiara M Dillworth; Neharika Chawla; Tracy L Simpson; Brian D Ostafin; Mary E Larimer; Arthur W Blume; George A Parks; G Alan Marlatt Journal: Psychol Addict Behav Date: 2006-09
Authors: Raymond F Anton; Stephanie S O'Malley; Domenic A Ciraulo; Ron A Cisler; David Couper; Dennis M Donovan; David R Gastfriend; James D Hosking; Bankole A Johnson; Joseph S LoCastro; Richard Longabaugh; Barbara J Mason; Margaret E Mattson; William R Miller; Helen M Pettinati; Carrie L Randall; Robert Swift; Roger D Weiss; Lauren D Williams; Allen Zweben Journal: JAMA Date: 2006-05-03 Impact factor: 56.272
Authors: Andrew J Waters; Lorraine R Reitzel; Paul Cinciripini; Yisheng Li; Marianne T Marcus; Jennifer Irvin Vidrine; David W Wetter Journal: Subst Abus Date: 2009 Oct-Dec Impact factor: 3.716
Authors: Jennifer Irvin Vidrine; Michael S Businelle; Paul Cinciripini; Yisheng Li; Marianne T Marcus; Andrew J Waters; Lorraine R Reitzel; David W Wetter Journal: Subst Abus Date: 2009 Oct-Dec Impact factor: 3.716
Authors: Sarah Bowen; Neharika Chawla; Susan E Collins; Katie Witkiewitz; Sharon Hsu; Joel Grow; Seema Clifasefi; Michelle Garner; Anne Douglass; Mary E Larimer; Alan Marlatt Journal: Subst Abus Date: 2009 Oct-Dec Impact factor: 3.716
Authors: Judson A Brewer; Rajita Sinha; Justin A Chen; Ravenna N Michalsen; Theresa A Babuscio; Charla Nich; Aleesha Grier; Keri L Bergquist; Deidre L Reis; Marc N Potenza; Kathleen M Carroll; Bruce J Rounsaville Journal: Subst Abus Date: 2009 Oct-Dec Impact factor: 3.716